Adefovir DipivoxilThird Party Manufacturing in India

Adefovir Dipivoxil works by inhibiting the hepatitis B virus (HBV) DNA polymerase.

It is an oral prodrug of adefovir, an acyclic nucleotide analogue of adenosine monophosphate. Once inside the cell, it is phosphorylated into its active diphosphate metabolite. This active form competes with natural substrates to bind to HBV DNA polymerase, becoming incorporated into the viral DNA. This incorporation causes DNA chain termination, halting the replication of the hepatitis B virus.

Unlike some earlier treatments, Adefovir Dipivoxil maintains efficacy even against lamivudine-resistant strains of HBV. It is highly effective and well-tolerated for patients requiring long-term suppression of chronic hepatitis B.

Therapeutic Uses

Adefovir Dipivoxil is prescribed for the treatment of:

• Chronic Hepatitis B: Indicated for the treatment of chronic hepatitis B in adults with evidence of active viral replication and persistent elevations in serum aminotransferases or histologically active disease.
• Lamivudine-Resistant HBV: Effective in patients who have developed resistance to lamivudine therapy.

Why Manufacturers Choose Adefovir Dipivoxil

Chronic Hepatitis B remains a major global health challenge, especially in developing nations. Adefovir Dipivoxil offers a reliable, once-daily oral treatment option that fits well into long-term disease management strategies.

This makes Adefovir Dipivoxil a steady and important molecule for third party manufacturing in India, fulfilling the consistent demand from hepatology-focused PCD franchises and global health initiatives.